Search Orphan Drug Designations and Approvals
-
Generic Name: | tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct |
---|---|
Date Designated: | 04/01/2020 |
Orphan Designation: | Treatment of T-cell lymphoma |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Affimed GmbH Im Neuenheimer Feld 582 Heidelberg Germany The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-